Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $3.8 million.

  • Gyre Therapeutics' Net Cash Flow rose 1213.65% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 962.01%. This contributed to the annual value of -$21.4 million for FY2024, which is 348.18% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Net Cash Flow stood at $3.8 million, which was down 82.49% from $21.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Net Cash Flow registered a high of $52.7 million during Q1 2021, and its lowest value of -$52.3 million during Q3 2022.
  • Over the past 3 years, Gyre Therapeutics' median Net Cash Flow value was -$337,000 (recorded in 2024), while the average stood at $1.4 million.
  • Per our database at Business Quant, Gyre Therapeutics' Net Cash Flow slumped by 372.39% in 2021 and then spiked by 1,213.65% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Net Cash Flow (Quarterly) stood at -$14.8 million in 2021, then plummeted by 81.57% to -$26.9 million in 2022, then soared by 174.15% to $19.9 million in 2023, then tumbled by 119.05% to -$3.8 million in 2024, then skyrocketed by 1,213.65% to $3.8 million in 2025.
  • Its Net Cash Flow was $3.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $3.2 million in Q1 2025.